By illuminating new avenues of investigation, therapeutic strategies targeting IRF7 or TBK-1 can be developed to boost vaccine responses to viral infections such as influenza and SARS-CoV-2 to alleviate substandard vaccine outcomes in the older population. Here, TBK1 is linked to influenza.